

#6

| | | | | | |
|---|---|----|---|--|--|
| PFO/SB/08A | | | | Complete if Known Application Number 10/009,447 Filing Date 11/13/01 First Named Inventor M. South et al. Attorney Docket No. 3203/1A/US(PHA 4159.26) | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | | |
| Sheet | 1 | of | 4 | | |

| U.S. PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|-------------------------|---|---|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Number | Kind Code ² (if known) | | |
| VB | 1 | 5,441,960 | B1 | Bernstein et al. | 08-15-1995 |
| VB | 2 | 5,656,645 | B1 | Tamura et al. | 08-12-1997 |
| VB | 3 | 5,658,930 | B1 | Tamura et al. | 08-19-1997 |
| VB | 4 | 5,668,289 | B1 | Sanderson et al. | 09-16-1997 |
| VB | 5 | 5,792,779 | B1 | Sanderson et al. | 08-11-1998 |
| VB | 6 | 5,861,380 | B1 | Gyorkos et al. | 01-19-1999 |
| VB | 7 | 5,866,573 | B1 | Sanderson et al. | 02-02-1999 |
| VB | 8 | 5,869,487 | B1 | Coburn et al. | 02-09-1999 |
| VB | 9 | 5,872,138 | B1 | Naylor-Olsen et al. | 02-16-1999 |
| VB | 10 | 6,011,158 | B1 | Tamura et al. | 01-04-2000 |
| VB | 11 | 6,037,356 | B1 | Lu et al. | 03-14-2000 |
| FOREIGN PATENT DOCUMENTS | | | | | |
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | T ⁶ |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | V. Balasubramanian | Date Considered | 8/28/03 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

| | | | | | |
|---|---|----|---|--------------------------|-------------------------|
| PTO/SB/08A | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 10/009,447 |
| | | | | Filing Date | 11/13/01 |
| | | | | First Named Inventor | M. South et al. |
| Sheet | 2 | of | 4 | Attorney Docket No. | 3203/1A/US(PHA 4159.26) |

| | | Office | Number ⁴ | Kind Code ² (if known) | | | |
|----|----|--------|---------------------|--------------------------------------|---|------------|--|
| VB | 12 | EP | 528 633 | B1 | Zeneca Limited | 02-24-1993 | |
| IM | 13 | EP | 826 671 | A1 | The Green Cross Corporation | 03-04-1998 | |
| M | 14 | EP | 936 216 | A1 | Nippon Kayaku Kabushiki Kaisha | 08-18-1999 | |
| VB | 15 | EP | 940 400 | A1 | Yoshitomi Pharmaceutical Industries, Ltd. | 09-08-1999 | |
| VB | 16 | EP | 997 474 | A1 | Pfizer Inc | 05-03-2000 | |
| VB | 17 | WO | 93/21214 | A1 | Zeneca Limited | 10-28-1993 | |
| M | 18 | WO | 96/18644 | A1 | Corvas International Inc. | 06-20-1996 | |
| VB | 19 | WO | 96/33974 | A1 | The Green Cross Corporation (abstract) | 10-31-1996 | |
| M | 20 | WO | 96/39380 | A1 | 3-Dimensional Pharmaceuticals, Inc. | 12-12-1996 | |
| B | 21 | WO | 96/40100 | A1 | 3-Dimensional Pharmaceuticals, Inc. | 12-19-1996 | |
| VB | 22 | WO | 97/01338 | A1 | Merck & Co., Inc. | 01-16-1997 | |
| M | 23 | WO | 97/30708 | A1 | Merck & Co., Inc. | 08-28-1997 | |
| VB | 24 | WO | 97/40024 | A1 | Merck & Co., Inc. | 10-30-1997 | |
| M | 25 | WO | 97/46207 | A2 | Corvas International Inc. | 12-11-1997 | |
| B | 26 | WO | 98/08840 | A1 | Merck & Co., Inc. | 03-05-1998 | |
| M | 27 | WO | 98/09949 | A1 | Nippon Kayaku Kabushiki Kaisha (abstract) | 03-12-1998 | |
| VB | 28 | WO | 98/10763 | A1 | Merck & Co., Inc. | 03-19-1998 | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | V. Belasubramanian | Date Considered | 8/28/03 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

| | | | | | |
|---|---|----|---|--------------------------|-------------------------|
| PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/009,447 |
| | | | | Filing Date | 11/13/01 |
| | | | | First Named Inventor | M. South et al. |
| Sheet | 3 | of | 4 | Attorney Docket No. | 3203/1A/US(PHA 4159.26) |


| | | | | | | | |
|----|----|----|----------|----|-------------------------------------|------------|--|
| M | 29 | WO | 98/16525 | A1 | Cor Therapeutics, Inc. | 04-23-1998 | |
| M | 30 | WO | 98/16547 | A1 | Cor Therapeutics, Inc. | 04-23-1998 | |
| M | 31 | WO | 98/17274 | A1 | Merck & Co., Inc. | 04-30-1998 | |
| M | 32 | WO | 98/31670 | A1 | Merck & Co., Inc. | 07-23-1998 | |
| VB | 33 | WO | 98/42342 | A1 | Merck & Co., Inc. | 10-01-1998 | |
| M | 34 | WO | 98/47876 | A1 | Akzo Nobel N.V. | 10-29-1998 | |
| VB | 35 | WO | 98/50420 | A1 | Akzo Nobel N.V. | 11-12-1998 | |
| VB | 36 | WO | 99/00121 | A1 | Eli Lilly and Company | 01-07-1999 | |
| M | 37 | WO | 99/00126 | A1 | Eli Lilly and Company | 01-07-1999 | |
| M | 38 | WO | 99/00128 | A1 | Eli Lilly and Company | 01-07-1999 | |
| VB | 39 | WO | 99/11267 | A1 | Merck & Co., Inc. | 03-11-1999 | |
| VB | 40 | WO | 99/26920 | A1 | Corvas Interantional, Inc. | 06-03-1999 | |
| M | 41 | WO | 99/26926 | A1 | 3-Dimensional Pharmaceuticals, Inc. | 06-03-1999 | |
| M | 42 | WO | 99/36426 | A1 | Warner-Lambert Company | 07-22-1999 | |
| VB | 43 | WO | 99/59591 | A1 | Merck & Co., Inc. | 11-25-1999 | |
| M | 44 | WO | 99/61442 | A1 | Merck & Co., Inc. | 12-02-1999 | |
| M | 45 | WO | 99/62538 | A1 | Cortech Inc. | 12-09-1999 | |
| M | 46 | WO | 99/64446 | A1 | 3-Dimensional Pharmaceuticals, Inc. | 12-16-1999 | |
| VB | 47 | WO | 00/18762 | A1 | Merck & Co., Inc. | 04-06-2000 | |
| VB | 48 | WO | 00/26210 | A1 | Merck & Co., Inc. | 05-11-2000 | |
| VB | 49 | WO | 00/26211 | A1 | Merck & Co., Inc. | 05-11-2000 | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | V. Balasubramanian | Date Considered | 8/28/03 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

| | | | | | |
|---|---|----|---|---|-------------------------|
| PTO/SB/08A | | | | <div style="text-align: center;">  </div> | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/009,447 |
| | | | | Filing Date | 11/13/01 |
| | | | | First Named Inventor | M. South et al. |
| Sheet | 4 | of | 4 | Attorney Docket No. | 3203/1A/US(PHA 4159.26) |

| | | | | | | | |
|----|----|----|----------|----|---------------------------------|------------|--|
| VS | 50 | WO | 00/32574 | A1 | Sanofi-Synthelabo (abstract) | 06-08-2000 | |
| VS | 51 | WO | 00/39102 | A1 | Du Pont Pharmaceuticals Company | 07-06-2000 | |
| VS | 52 | WO | 00/69826 | A1 | Monsanto Company | 11-23-2000 | |
| VS | 53 | WO | 00/69832 | A1 | Monsanto Company | 11-23-2000 | |
| VS | 54 | WO | 00/69833 | A1 | Monsanto Company | 11-23-2000 | |

OTHER ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| M | 55 | MAJERUS, et al. "Anticoagulant, Thrombolytic, and Antiplatelet Drugs." Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, 1996, pp. 1341-1359, McGraw-Hill, New York. | |
| M | 56 | HANDIN, R., "Bleeding and Thrombosis." Harrison's Principles of Internal Medicine, 12th Edition, 1991, pp. 348-353, McGraw-Hill, Inc., New York. | |
| M | 57 | SANDERSON et al., "L-373,890, An Achiral, Noncovalent, Subnanomolar Thrombin Inhibitor." Bioorganic & Medicinal Chemistry Letters, Vol. 7, No. 12, pp. 1497-1500, 1997. | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | V. Balasubramanian | Date Considered | 8/28/03 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.